Sandeepa Musunuru1, Gretchen Beverstein, Jon Gould. 1. Department of Surgery, University of Wisconsin School of Medicine and Public Health, H4/726 Clinical Science Center, 600 Highland Avenue, Madison, WI, 53792, USA. SMusunuru@uwhealth.org
Abstract
BACKGROUND: In cases of gastroparesis where significant symptoms fail to respond to standard medical therapy, gastric electrical stimulation (GES) may be of benefit. Unfortunately, not all patients improve with this therapy. Reliable preoperative predictors of symptomatic response to GES may allow clinicians to offer this expensive and invasive treatment to only those patients most likely to benefit. METHODS: Therapy was initiated in 15 patients more than 12 months prior to this retrospective review of our prospectively maintained data. All patients completed a Total Symptom Score (TSS) survey at every encounter as well as the SF-36 quality-of-life instrument prior to surgery. A failure of GES therapy was considered to have occurred when after 1 year of treatment, preoperative TSS had not decreased by at least 20%. RESULTS: Four patients (4 idiopathic) failed to improve more than 20% on multiple assessments after a year of therapy. All diabetic patients experienced a durable symptomatic improvement with GES. Review of individual items of the TSS revealed that nonresponders experienced less severe vomiting preoperatively. CONCLUSIONS: Diabetic gastroparesis patients respond best to GES. Responders tend to have more severe vomiting preoperatively. Patients with idiopathic gastroparesis who do not experience severe vomiting should be cautioned about a potentially higher rate of poor response to GES and may be better served with alternative treatments.
BACKGROUND: In cases of gastroparesis where significant symptoms fail to respond to standard medical therapy, gastric electrical stimulation (GES) may be of benefit. Unfortunately, not all patients improve with this therapy. Reliable preoperative predictors of symptomatic response to GES may allow clinicians to offer this expensive and invasive treatment to only those patients most likely to benefit. METHODS: Therapy was initiated in 15 patients more than 12 months prior to this retrospective review of our prospectively maintained data. All patients completed a Total Symptom Score (TSS) survey at every encounter as well as the SF-36 quality-of-life instrument prior to surgery. A failure of GES therapy was considered to have occurred when after 1 year of treatment, preoperative TSS had not decreased by at least 20%. RESULTS: Four patients (4 idiopathic) failed to improve more than 20% on multiple assessments after a year of therapy. All diabeticpatients experienced a durable symptomatic improvement with GES. Review of individual items of the TSS revealed that nonresponders experienced less severe vomiting preoperatively. CONCLUSIONS:Diabetic gastroparesispatients respond best to GES. Responders tend to have more severe vomiting preoperatively. Patients with idiopathic gastroparesis who do not experience severe vomiting should be cautioned about a potentially higher rate of poor response to GES and may be better served with alternative treatments.
Authors: D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack Journal: Aliment Pharmacol Ther Date: 2003-07-01 Impact factor: 8.171
Authors: Richard W McCallum; Reginald W Dusing; Irene Sarosiek; Jose Cocjin; Jameson Forster; Zhiyue Lin Journal: Conf Proc IEEE Eng Med Biol Soc Date: 2006
Authors: Nancy Salloum Harrison; Patrick A Williams; Micah R Walker; Yana Nikitini; Thomas S Helling; Thomas L Abell; Christopher J Lahr Journal: Surg Innov Date: 2013-09-20 Impact factor: 2.058
Authors: Michael Camilleri; Braden Kuo; Linda Nguyen; Vida M Vaughn; Jessica Petrey; Katarina Greer; Rena Yadlapati; Thomas L Abell Journal: Am J Gastroenterol Date: 2022-06-03 Impact factor: 12.045
Authors: Sarah Marowski; Yiwei Xu; Jake A Greenberg; Luke M Funk; Anne O Lidor; Amber L Shada Journal: Surg Endosc Date: 2020-10-06 Impact factor: 4.584
Authors: Denise Strijbos; Daniel Keszthelyi; Fabiënne G M Smeets; Joanna Kruimel; Lennard P L Gilissen; Rogier de Ridder; José M Conchillo; Ad A M Masclee Journal: Neurogastroenterol Motil Date: 2019-04-04 Impact factor: 3.598